Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GUFICBIO.NS
BuyPremium GrowerGufic Biosciences Limited · Healthcare · India · $466M · Avg Vol: $545K/d
71
StockRankGet insider-trade alerts
Q
59
V
18
M
89
P/E (TTM)
59.7x
ROE
9.7%
D/E
0.6x
Dividend %
0.0%
COMPANY DESCRIPTION
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 6.8B | 7.7B | 7.5B | 8.1B | 6.1% | 9.8B |
| EPS (INR) | 8.22 | 8.74 | 6.95 | 6.40 | -8.0% | 7.18 |
| Shares | 96.9M | 100.3M | 100.3M | 100.3M | +3.4% | 100.3M |
| Debt | 3.3B | 3.3B | 3.4B | 4.0B | 6.6% | 4.0B |
| Equity | 3.5B | 5.3B | 6.0B | 6.6B | 24.1% | — |
| Op CF | -265.9M | -74.6M | 1.2B | 451.4M | -63.2% | 451.4M |
| Inv CF | -1.9B | -1.0B | -707.8M | -309.6M | — | — |
| Fin CF | 2.3B | 823.8M | -372.0M | 322.9M | — | — |
Loading 1Y...
PRICE (1Y)+12.2%
SMA 50SMA 200
Close
$4.51
RSI (14)
53.2
52W High
$4.77
From 52W High
0.9%
SCORE BREAKDOWN
Quality
59
ROIC
16.5%86.0
ROE
9.7%69.0
GP/Assets
40.0%77.6
Op. Margin
14.9%74.7
FCF/Assets
1.0%50.5
Piotroski
431.0
Int. Cover
3.7x47.8
D/E Ratio
0.61x24.6
Current Ratio
1.55x27.6
Value
18
P/E (TTM)
59.7x17.4
EV/EBITDA
29.7x21.7
P/FCF
317.4x5.5
P/B
6.5x20.9
P/S
4.4x45.2
Div Yield
0.0%0.8
Momentum
89
52W High %
94%92.7
RS 6M
52%91.5
SMA 50/200
1.19x87.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
71%79.9
FUNDAMENTALS
Market Cap
$466M
P/E (Forward)
—
Gross Margin
54.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GUFICBIO.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GUFICBIO.NS | Gufic Biosciences Limited(you) | $466M | 71 | Buy |
| RPGLIFE.NS | RPG Life Sciences Limited | $489M | 79 | Buy |
| FDC.NS | FDC Limited | $594M | 76 | Buy |
| HIKAL.NS | Hikal Limited | $320M | 75 | Buy |
| AARTIDRUGS.NS | Aarti Drugs Limited | $406M | 80 | Strong Buy |
| BETA.NS | Beta Drugs Limited | $228M | 72 | Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited | $356M | 81 | Strong Buy |
| INNOVACAP.NS | Innova Captab Limited | $707M | 79 | Buy |
| AARTIPHARM.NS | Aarti Pharmalabs Limited | $829M | 65 | Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%